UBS launches coverage on several big pharma names

Some more big pharma coverage from UBS has the team initiating Novartis (NVS +0.4%) with a Buy rating. Started at Neutral are GlaxoSmithKline (GSK) and Sanofi (SNY -0.5%).

Earlier: AstraZeneca is initiated a Buy.

From other sites
Comments (1)
  • old bear 35
    , contributor
    Comment (1) | Send Message
    bot this stock three years ago for the's been a good one to hold on to
    12 Jan 2014, 11:59 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs